BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula,as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment of autoimmune and inflammatory diseases associated with Inte...

Full description

Saved in:
Bibliographic Details
Main Authors DEHNHARDT Christoph Martin, WANG Xiaolun, HUANG Horng-Chih, PIERCE Betsy Susan, WRIGHT Stephen Wayne, LOVERING Frank Eldridge, ANDERSON David Randolph, HEPWORTH David, LEE Katherine Lin, PAPAIOANNOU Nikolaos, LEE Arthur, BUNNAGE Mark Edward, GOLDBERG Joel Adam, HAN Seungil, CURRAN Kevin Joseph, LOWE Michael Dennis, PATNY Akshay, STROHBACH Joseph Walter, GAVRIN Lori Krim, MATHIAS John Paul, ZAPF Christoph Wolfgang, TRZUPEK John David, VARGAS Richard, SAIAH Eddine
Format Patent
LanguageEnglish
Slovenian
Published 31.05.2019
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online AccessGet full text

Cover

More Information
Summary:Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula,as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment of autoimmune and inflammatory diseases associated with Interleukin-1 Receptor Associated Kinase (IRAK), methods of synthesis, and intermediates are also disclosed.
Bibliography:Application Number: SI20150030676T